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Abstract
The presence of CBFA2T3-GLIS2 fusion gene has been identified in childhood Acute
Myeloid Leukemia (AML). In view of the genomic studies indicating a distinct gene
expression profile, we evaluated the role of immunophenotyping in characterizing a
rare subtype of AML-CBFA2T3-GLIS2 rearranged. Immunophenotypic data were
obtained by studying a cohort of 20 pediatric CBFA2T3-GLIS2-AML and 77 AML
patients not carrying the fusion transcript. Enrolled cases were included in the
Associazione Italiana di Ematologia Oncologia Pediatrica (AIEOP) AML trials and
immunophenotypes were compared using different statistical approaches. By multi-
ple computational procedures, we identified two main core antigens responsible for
the identification of the CBFA2T3-GLIS2-AML. CD56 showed the highest perfor-
mance in single marker evaluation (AUC = 0.89) and granted the most accurate pre-
diction when used in combination with HLA-DR (AUC = 0.97) displaying a 93%
sensitivity and 99% specificity. We also observed a weak-to-negative CD45 expres-
sion, being exceptional in AML. We here provide evidence that the combination of
HLA-DR negativity and intense bright CD56 expression detects a rare and aggressive
pediatric AML genetic lesion improving the diagnosis performance.
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1 | INTRODUCTION
A recurrent cryptic inversion of chromosome 16 [inv (16)
(p13.3q24.3)] fuses a portion of CBFA2T3 gene in frame with a region
of GLIS2 gene encoding for CBFA2T3-GLIS2 fusion transcript [1,2].
This chimeric oncogene accounts for 18% of pediatric non-Down syn-
drome acute megakaryoblastic leukemia (non-DS-AMKL) patients and
8% of pediatric cytogenetically normal AML (CN-AML) associated
with different French-American-British (FAB) subtypes [1–3]. This
genetic lesion confers a particularly poor prognosis, with event-free
survival (EFS) ranging between 8% and 33% in different studies [1–5].
The gene expression profile of CBFA2T3-GLIS2 AML has been associ-
ated with up-regulation of both Hedgehog (HH) and bone
morphogenic protein (BMP) signaling [2,6,7]. In view of the genomic
studies indicating a distinct gene expression profile compared with
other genetic subtypes of childhood AML [2], we evaluated the
immunophenotypic profile of pediatric AML CBFA2T3-GLIS2
rearranged.
2 | MATERIALS AND METHODS
From April 2001 to March 2017, we identified 25 CBFA2T3-GLIS2-
positive cases. Five samples were excluded from this analysis due to
missing immunophenotypic data. The immunophenotype of
20 CBFA2T3-GLIS2-positive cases was compared with a cohort of
77 CBFA2T3-GLIS2-negative AML patients, including also two cases
of Down syndrome myeloid leukemia (ML-DS) and nine cases of acute
promyelocytic leukemia (APL), collected in the same time interval. All
patients were enrolled in the Associazione Italiana di Ematologia
Oncologia Pediatrica (AIEOP) AML trials (AIEOP AML 2002, AIEOP
ICC APL Study 01). The biological material used in this study was cen-
tralized at the Pediatric Hematology Oncology reference AIEOP Labo-
ratory of Padua. Clinical features are detailed in Table 1, data on
molecular genetics in Table S1. Written informed consent to the use
of the patient's data and biological material was obtained from par-
ents/legal guardians in accordance with the Declaration of Helsinki.
Local institutional ethical committees approved the study, including
TABLE 1 Clinical characteristics for
non-DS and non-APL AML patients
(CBFA2T3-GLIS2 positive and negative)
enrolled in the study
CBFA2T3-GLIS2 positive CBFA2T3-GLIS2 negative
p
N % N %
Total cohort 18 100 66 100
Age (years)
<10 18 100 36 54.5 <0.01
>10 0 0 30 45.5 <0.01
Gender
Female 10 55.6 37 56.1 0.11
Male 8 44.4 29 43.9 0.11
WBC
≤10,000 3 16.7 23 34.8 0.16
10,000 ≤ 100,000 15 83.3 37 56.1 0.05
>100,000 0 0 6 9.1 0.33
FAB
M0 0 0 2 3 1
M1 1 5.5 6 9.1 1
M2 1 5.5 20 27.4 0.06
M2Eo 0 0 2 3 1
M4 0 0 17 25.8 0.02
M4Eo 0 0 1 1.5 1
M5 1 5.5 11 16.7 0.44
M6 0 0 1 1.5 1
M7 14 78.0 3 4.5 <0.01
Other 1 5.5 5 7.5 1
BM blasts (median %) 50 64 0.37
Extramedullary involvementa 4 22.2 6 9.1 0.21
Note: p values have been calculated using Fisher's statistics. The bold values denote statistical
significance at the p < 0.05 level.
aOne patient with additional CNS involvement, three patients without CNS involvement.
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the collection of bone marrow samples (BM) for diagnostic work-up,
along with the national protocols. Diagnosis of de novo AML was per-
formed according to WHO classification criteria [8,9]. Samples were
screened for the presence of t(8;21), inv(16), t(16;16), t(15;17) with
associated molecular transcripts, namely core-binding factor (CBF)-β
abnormalities and PML-RARα; moreover, KMT2A rearrangements
[9,10], Internal Tandem Duplication of FLT3 mutation (FLT3-ITD) [11]
and other rare mutations were screened (Table S1).
2.1 | Flow cytometry
Initial evaluation of qualitative results from the whole
immunophenotypic characterization was performed at diagnosis
according to WHO criteria and the latest consensus guidelines for
flow-cytometry immunophenotyping published by the AIEOP-BFM
working group [12]. Quantitative values of mean fluorescence inten-
sity (MFI) was retrieved for 14 antigens: CD45 ECD, HLA-DR PE-Cy7,
CD56 PE, CD11a PE, CD11b PE, CD13 FITC, CD15 FITC, CD41 FITC,
CD61 PE-Cy7, CD38 PE-Cy5, Myeloperoxidase (MPO) FITC, CD33
PE-Cy5, CD34 PE-Cy5, and CD117 PE. Samples were processed and
analyzed in the Hemato Oncology Laboratory of Padua, according to
standardized operating procedures (SOP) previously described [8,12].
Flow cytometry methods have been detailed in a Supplementary doc-
ument according to MIFlowCyt standards.
2.2 | Statistical analyses
Statistical procedures were performed to identify putative antigens
correlated with the presence of CBFA2T3-GLIS2 mutation and esti-
mate their accuracy in classifying patients as “GLIS” (with mutation)
or “nGLIS” (without mutation) samples. All statistical analyses were
performed using R software [13]: Random Forest analyses including
Mean Decrease in Accuracy (MDA) and Mean Decrease in Gini coeffi-
cient (MDG) procedures were performed using “randomForest” pack-
age [14]; multiple testing corrections were evaluated with “multtest”
package [15]; permutation tests were retrieved using k-Nearest
Neighbor classifier and “caret” package; classification model's perfor-
mance was evaluated using Area Under Receiver Operating Charac-
teristics (AUROC or AUC) calculated with “ROCR” package; principal
component analysis (PCA) was obtained using “factoextra” and
“factoMiner” packages. Figure 1A summarizes the analysis steps per-
formed in the whole study starting from cohort description through
feature selection, classification, and performance, ending to spatial
visualization of the results.
3 | RESULTS AND DISCUSSION
Ninety-seven patients were investigated for antigen (N = 14) associa-
tions using different computational analyses (Figure 1A). First, super-
vised random forests analysis was performed to measure the
importance of all variables and their ability in classifying the data
appropriately [14]. MDA reflects the impact of each antigen on the
accuracy of the prediction, model-antigens with a large mean
decrease in accuracy, being more important for classification. As
shown in Figure 1B, CD56 and HLA-DR antigens were the most accu-
rate markers for the identification of “GLIS” AML cases in MDA evalu-
ation; MDG (Figure 1C) confirmed MDA results, as detailed in
Table S2. The same markers were identified by antigen selection
F IGURE 1 Variable selection procedures and data presentation.
(A) Analysis steps performed from cohort description to spatial
visualization of the results. (B) Mean decrease in accuracy (MDA)
results using “randomForest” package in R software. CD56 and HLA-
DR have the largest mean decrease scores and are considered the
most accurate antigens for classification of the data. (C) Mean
decrease in Gini (MDG) coefficient confirms CD56 and HLA-DR
antigens as the most accurate markers in separating “GLIS” and
“nGLIS” patients. (D) Principal component analysis (PCA) results using
“factoextra” and “factoMiner” packages. “GLIS” patients (in red) are
associated with CD56 expression, while “nGLIS” group (in blue) with
HLA-DR
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based on Wilcoxon's test and Bonferroni procedure for multiple test-
ing corrections [15]. As shown in Table S3, CD56 (p = 0.00014) and
HLA-DR (p = 0.00014) were the most discriminating markers followed
by CD45 (p = 0.00686), MPO (p = 0.00882), CD38 (p = 0.01932), and
CD11a (p = 0.02282). To test the classification strength of identified
markers, for each of the 10,000 permutations we randomly assigned
patients either to training (total N = 64: N = 13 “GLIS”, N = 51
“nGLIS”) or validation (total N = 33: N = 7 “GLIS,” N = 26 “nGLIS”)
sets. We further calculated the performance of the two markers and
their combination in classifying “GLIS” and “nGLIS” patients using
ROC curves. Weighted mean (WM) was calculated for accuracy mea-
sures including sensitivity, specificity, PPV (positive predictive value),
and NPV (negative predictive value) as well as for AUC permutations.
CD56 held the highest score in single-marker model evaluation
(AUC = 0.89) followed by HLA-DR (AUC = 0.86): remarkably, their
combination granted the most accurate model prediction with
AUC = 0.97, as well as the highest weighted mean sensitivity (0.93),
specificity (0.99), PPV (0.96), and NPV (0.98). Biplot (PCA) was per-
formed on all patients using only CD56 and HLA-DR to clearly show
the correlation between groups and antigens supporting the strength
of the selected signature (Figure 1D): “GLIS” group was strongly asso-
ciated with expression of CD56, while “nGLIS” correlated mainly with
HLA-DR antigen expression (details in Table S4).
The aim of this study was to evaluate the role of multiparametric
flow cytometry analysis in the identification of CBFA2T3-GLIS2 posi-
tive AML as previously reported for other genetic subtypes. Our
results show that the combination of low HLA-DR together with
CD56 as intensive bright provides the highest accuracy in classifying
an AML case as “GLIS.” The lack of HLA-DR is one of the most sensi-
tive feature typical of APL with respect to other AML subtypes [16]
and is described as negative also in some NPM1-mutated AMLs [17–
19]. Antibodies against CD56 are primarily used to detect natural
killer (NK) cells but are also useful in the evaluation of pediatric solid
tumors, such as neuroendocrine and neuroectodermal malignancies
(e.g., neuroblastoma, primitive neuroectodermal tumor) [20, 21]. We
attempted a CD56 intensity comparison in GLIS-AML and a solid
tumor finding a comparable CD56 bright expression (Figures 2 and
S1A,B). In AML, CD56 expression has been frequently associated with
t(8;21) RUNX1-RUNX1T1 [22] but with a lower intensity than com-
pared with “GLIS” cases. Thiollier et al. previously showed that
CBFA2T3-GLIS2+ AMKL exhibits a distinct gene-expression signature:
surface marker NCAM1 (CD56) presented a mean differential expres-
sion of 35-fold by microarray and of more than 200-fold by RNA-seq
with respect to other non-DS AMKL. Using flow-cytometry, they also
observed that AMKL blasts carrying CBFA2T3-GLIS2 fusion were
CD41+/CD56 + [6]. In our cohort, we observed by flow cytometry a
CD56 median differential expression of 29-fold with respect to AML
nGLIS (Figure S1B). Moreover, in diagnostic immunophenotyping
either lack of or low expression of CD45 is uncommon in AML
(Figure S1A); negativity for CD45 associated with positivity for CD56
could be suggestive of non-hematological malignancies [20,21]. In the
group of “GLIS” patients here described, CD45 was under-expressed
with respect to other AML subtypes (not statistically relevant).
The peculiar immunophenotype we discuss also matches the RAM
phenotype described by Eidenschink Brodersen et al. [23] The RAM
phenotype was characterized by bright CD56, dim-to-negative CD45
and CD38, lack of HLA-DR; it was primarily restricted to very young
patients and associated with an extremely poor outcome [23,24].
Pardo et al., investigated the relationship between CD56 expression
and prognosis in AML patients enrolled in the Children's Oncology
Group Trial AAML0531 [25]. In particular, their Cohort 3 was charac-
terized by a unique immunophenotype (RAM phenotype) and a high
prevalence of patients with CBFA2T3-GLIS2 fusion transcript. In our
study, we corroborate a highly specific immunophenotype for this
fusion transcript in an independent cohort of patients enrolled in the
AIEOP study. Analysis of our patients' characteristics confirmed that
the CBFA2T3-GLIS2 rearrangement is typical of very young children
[26] and is not restricted to M7 subtype (Table 1) [1]. Although, despite
this characteristic immunophenotype, no morphological aspects were
F IGURE 2 Flow cytometry analyses of BM samples.
CBFA2T3-GLIS2 positive AML immunophenotype (Case 1) may be
misinterpreted with non-hematopoietic tumors BM involvement
(Case 2) due to the comparable high expression of CD56 and
downregulation of CD45
4 ZANGRANDO ET AL.
suggestive for “GLIS”: BM smears could also mimic BM invasion by
non-hematopoietic tumors (Figure 3A–D). Clinical features at leukemia
presentation could include extramedullary involvement: frequency of
extramedullary leukemia in our CBFA2T3-GLIS2 patients was higher
(22.2%, Table 1) than that described in pediatric AML [27]. Notably, in
two of four cases, extramedullary involvement (including massive cra-
nial bone, ribs, and lumbosacral column involvement, respectively) pri-
marily raised the suspicion of non-hematopoietic tumor instead of
acute leukemia.
Accurate diagnosis of childhood hematological malignancies is
often challenging and based on the combination of morphology, flow
cytometry, cytogenetics, and molecular biology data. Here, we
describe an immunophenotypic profile specific for a rare cytogenetic
lesion (CBFA2T3-GLIS2), clearly discriminated from other AML sub-
types and characterized by weak-to-negative CD45 expression
unusual in AML, HLA-DR negativity (a finding uncommon in AML
apart from APL and NPM1-mutated cases), and intense bright CD56
expression (more suggestive of non-hematological malignancies). This
immunophenotypic profile not suggestive of AML could be associated
with clinical presentation and BM morphologic features that overlap
non-hematopoietic tumors as shown in some of our patients.
In the presence of symptoms related to organ failure or
extramedullary involvement, in young children with no clear diagnosis
of solid tumors, we propose to add a BM aspirate to the diagnostic
workup, even if peripheral blood count does not portend leukemia
diagnosis. Whenever suspicious tumor cells are detected, further com-
prehensive phenotypic characterization must be performed. Immuno-
phenotyping by flow cytometry is mandatory for a correct AML
diagnosis and can provide the indication of molecular biology before
other invasive diagnostic procedures are planned.
Overall, our study supports a specific immunophenotype highly
suggestive of the AML subtype carrying CBFA2T3-GLIS2
rearrangement. Our results indicate that an accurate flow cytometry
evaluation of leukemia cells at diagnosis allows a rapid identification
of this AML subtype even when AML morphological aspect and clini-
cal presentation may not be suggestive of this rare and aggressive
pediatric AML entity.
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